Treatment With Namenda in Women at Risk for Cognitive Decline

Trial ID or NCT#

NCT00242632

Status

not recruiting iconNOT RECRUITING

Purpose

This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.

Official Title

Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study

Eligibility Criteria

Ages Eligible for Study: 50 Years to 65 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. : - Women between the ages of 50-65 - Willing to sign Human Subjects Protection Consent Form - Personal or family history of mood disorder - Hypothyroidism - Diabetes - Family history of Alzheimer's disease
Exclusion Criteria:
  1. - Possible or probable Alzheimer's disease or dementia - History of cerebrovascular disease - History of myocardial infarction within the previous year - History of unstable heart disease - Uncontrolled hypertension - Less than 8 years of education - English as a 2nd language - Uncorrected vision or hearing deficits

Investigator(s)

Natalie L. Rasgon
Natalie L. Rasgon
Psychiatrist
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult) at the Stanford University Medical Center, Emerita

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM